Vesey Street

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Monday, December 4, 2023

Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Equity capital markets, Exercise, Security (finance)

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.

Key Points:

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.
The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets acted as joint book-running managers for the offering.
The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

Retrieved on:

Friday, December 1, 2023

Telephone, ATTN:, Sale, Jefferies Group, BMO Capital Markets, Attention, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Guggenheim Partners, Equity capital markets, Security (finance), Exercise

The total gross proceeds of the public offering were approximately $143.8 million, before deducting underwriting discounts and commissions and offering expenses payable by Verve.

Key Points:

The total gross proceeds of the public offering were approximately $143.8 million, before deducting underwriting discounts and commissions and offering expenses payable by Verve.
All of the shares in the public offering were sold by Verve.
In addition, Verve today announced the closing of its previously announced private placement of 2,296,317 shares of its common stock to Eli Lilly and Company, at a price per share equal to the public offering price.
Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets acted as joint book-running managers for the public offering.

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

Retrieved on:

Thursday, November 30, 2023

Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Broadridge Financial Solutions, Equity capital markets, Security (finance)

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.

Key Points:

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.
In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,384,615 common shares at the public offering price, less the underwriting discounts and commissions.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.
These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.

Xenon Pharmaceuticals Announces Proposed Public Offering

Retrieved on:

Wednesday, November 29, 2023

All of the common shares and pre-funded warrants in this offering are being offered by Xenon.

Key Points:

All of the common shares and pre-funded warrants in this offering are being offered by Xenon.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are acting as joint book-running managers for the proposed offering.
An automatically effective shelf registration statement relating to the securities offered in the proposed public offering described above was filed with the Securities and Exchange Commission (SEC) on October 4, 2021.

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

Retrieved on:

Wednesday, November 29, 2023

Telephone, ATTN:, Verve, Sale, Jefferies Group, BMO Capital Markets, Attention, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Guggenheim Partners, Equity capital markets, Security (finance), Exercise

All of the shares in the public offering are being sold by Verve.

Key Points:

All of the shares in the public offering are being sold by Verve.
In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
The public offering and concurrent private placement are expected to close on December 1, 2023, subject to the satisfaction of customary closing conditions.
Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Retrieved on:

Tuesday, November 28, 2023

In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points:

In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
The shares will be sold to Lilly at a price per share equal to the public offering price.
The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the public offering and concurrent private placement may be completed, or as to the actual size or terms of the public offering and concurrent private placement.
Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.

AerSale Announces Pricing of Secondary Offering of Common Stock

Retrieved on:

Thursday, December 14, 2023

AerSale Corporation (“AerSale”) (NASDAQ: ASLE), a leading provider of aviation products and services, today announced the pricing of the previously announced underwritten secondary offering (the “Offering”) by affiliates of Leonard Green & Partners, L.P. (the “Selling Stockholders”), of 4,000,000 shares of common stock of AerSale pursuant to a shelf registration statement on Form S-3 filed by AerSale with the U.S. Securities and Exchange Commission (the “SEC”).

Key Points:

AerSale Corporation (“AerSale”) (NASDAQ: ASLE), a leading provider of aviation products and services, today announced the pricing of the previously announced underwritten secondary offering (the “Offering”) by affiliates of Leonard Green & Partners, L.P. (the “Selling Stockholders”), of 4,000,000 shares of common stock of AerSale pursuant to a shelf registration statement on Form S-3 filed by AerSale with the U.S. Securities and Exchange Commission (the “SEC”).
The Selling Stockholders have granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock on the same terms and conditions.
No shares are being issued or sold by AerSale.
The Selling Stockholders will receive all of the proceeds from the Offering.

AerSale Announces Secondary Offering of Common Stock

Retrieved on:

Wednesday, December 13, 2023

Air, Transport, Aerospace, Manufacturing, Sale, Telephone, Attention, Leonard Green & Partners, Vesey Street, S-3, Form, Partner, AerSale, Capital market, Prospectus, RBC Capital Markets, Equity capital markets, Offering, Security (finance)

AerSale Corporation (“AerSale”) (NASDAQ: ASLE), a leading provider of aviation products and services, today announced that certain of its stockholders, including affiliates of Leonard Green & Partners, L.P. (the “Selling Stockholders”) intend to offer for sale in an underwritten secondary offering (the “Offering”) 4,000,000 shares of common stock of AerSale pursuant to a shelf registration statement on Form S-3 filed by AerSale with the U.S. Securities and Exchange Commission (the “SEC”).

Key Points:

AerSale Corporation (“AerSale”) (NASDAQ: ASLE), a leading provider of aviation products and services, today announced that certain of its stockholders, including affiliates of Leonard Green & Partners, L.P. (the “Selling Stockholders”) intend to offer for sale in an underwritten secondary offering (the “Offering”) 4,000,000 shares of common stock of AerSale pursuant to a shelf registration statement on Form S-3 filed by AerSale with the U.S. Securities and Exchange Commission (the “SEC”).
The Selling Stockholders expect to grant the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock on the same terms and conditions.
No shares are being issued or sold by AerSale.
The Selling Stockholders will receive all of the proceeds from the Offering.

Kinetik Announces Pricing of Upsized Secondary Offering of Common Stock

Retrieved on:

Tuesday, December 12, 2023

Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced today the pricing of an upsized underwritten secondary offering of 6,500,000 shares of its Class A common stock (the “Offering”) by Apache Midstream LLC (the “Selling Stockholder”), a subsidiary of Apache Corporation, at a price of $31.50 per share.

Key Points:

Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced today the pricing of an upsized underwritten secondary offering of 6,500,000 shares of its Class A common stock (the “Offering”) by Apache Midstream LLC (the “Selling Stockholder”), a subsidiary of Apache Corporation, at a price of $31.50 per share.
Kinetik is not selling any shares of Class A common stock in the Offering and will not receive the proceeds from any sale of shares by the Selling Stockholder.
The Offering was upsized from the previously announced 6,000,000 shares based on strong investor demand.
The Selling Stockholder has granted to the underwriters a 30-day option to purchase up to an additional 975,000 shares of Kinetik’s Class A common stock.

Kinetik Announces Secondary Offering of Common Stock

Retrieved on:

Monday, December 11, 2023

Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced today the commencement of an underwritten secondary offering of 6,000,000 shares of its Class A common stock (the “Offering”) by Apache Midstream LLC (the “Selling Stockholder”), a subsidiary of Apache Corporation.

Key Points:

Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced today the commencement of an underwritten secondary offering of 6,000,000 shares of its Class A common stock (the “Offering”) by Apache Midstream LLC (the “Selling Stockholder”), a subsidiary of Apache Corporation.
Kinetik is not selling any shares of Class A common stock in the Offering and will not receive the proceeds from any sale of shares by the Selling Stockholder.
In connection with the Offering, the Selling Stockholder intends to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of Kinetik’s Class A common stock.
In connection with the Offering, certain of the Company’s officers and directors, including the Chief Executive Officer, have provided an indication of interest in purchasing shares of Class A common stock from the underwriters at the public offering price.